公开(公告)号：US06369086B1

公开(公告)日：2002-04-09

申请号：US09262351

申请日：1999-03-04

申请人： Stephen Thomas Davis ,  Scott Howard Dickerson ,  Philip Anthony Harris ,  Robert Neil Hunter, III ,  Lee Frederick Kuyper ,  Karen Elizabeth Lackey ,  Michael Joseph Luzzio ,  James Marvin Veal ,  Duncan Herrick Walker

发明人： Stephen Thomas Davis ,  Scott Howard Dickerson ,  Philip Anthony Harris ,  Robert Neil Hunter, III ,  Lee Frederick Kuyper ,  Karen Elizabeth Lackey ,  Michael Joseph Luzzio ,  James Marvin Veal ,  Duncan Herrick Walker

IPC分类号： A61K314439

CPC分类号： C07D231/12 ,  C07D209/34 ,  C07D209/40 ,  C07D233/56 ,  C07D249/08 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D413/04 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D513/04

摘要： The present invention relates generally to novel substituted oxindole compounds and compositions. Such compounds and compositions have utility as pharmacological agents in treating diseases or conditions alleviated by the inhibition or antagonism of protein kinase activated signalling pathways. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit protein tyrosine kinase and protein serine/threonine kinase inhibition, and which are useful in inhibiting tumor growth via inhibition of such kinases as well as protecting a patient undergoing chemotherapy from chemotherapy induced alopecia.

摘要翻译： 本发明一般涉及新型取代的羟基吲哚化合物和组合物。 这样的化合物和组合物可用作治疗通过抑制或拮抗蛋白激酶激活的信号通路而减轻的疾病或病症的药理学作用。 特别地，本发明涉及一系列取代的羟吲哚化合物，其表现出蛋白质酪氨酸激酶和蛋白质丝氨酸/苏氨酸激酶抑制，并且其可用于通过抑制这种激酶抑制肿瘤生长以及保护接受化疗的患者 化疗引起秃发。

公开(公告)号：US07105529B2

公开(公告)日：2006-09-12

申请号：US09999331

申请日：2001-11-30

申请人： Stephen Thomas Davis ,  Scott Howard Dickerson ,  Stephen Vernon Frye ,  Philip Anthony Harris ,  Robert Neil Hunter, III ,  Lee Frederick Kuyper ,  Karen Elizabeth Lackey ,  Michael Joseph Luzzio ,  James Marvin Veal ,  Duncan Herrick Walker

发明人： Stephen Thomas Davis ,  Scott Howard Dickerson ,  Stephen Vernon Frye ,  Philip Anthony Harris ,  Robert Neil Hunter, III ,  Lee Frederick Kuyper ,  Karen Elizabeth Lackey ,  Michael Joseph Luzzio ,  James Marvin Veal ,  Duncan Herrick Walker

IPC分类号： A61K31/505 ,  A61K31/44 ,  A61K31/425

CPC分类号： C07D231/12 ,  C07D209/34 ,  C07D209/40 ,  C07D233/56 ,  C07D249/08 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D413/04 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D513/04

摘要： Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydrogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.

公开(公告)号：US06541503B2

公开(公告)日：2003-04-01

申请号：US09924431

申请日：2001-08-08

申请人： Stephen Thomas Davis ,  Scott Howard Dickerson ,  Stephen Vernon Frye ,  Philip Anthony Harris ,  Robert Neil Hunter, III ,  Lee Frederick Kuyper ,  Karen Elizabeth Lackey ,  Michael Joseph Luzzio ,  James Marvin Veal ,  Duncan Herrick Walker

发明人： Stephen Thomas Davis ,  Scott Howard Dickerson ,  Stephen Vernon Frye ,  Philip Anthony Harris ,  Robert Neil Hunter, III ,  Lee Frederick Kuyper ,  Karen Elizabeth Lackey ,  Michael Joseph Luzzio ,  James Marvin Veal ,  Duncan Herrick Walker

IPC分类号： A61K31429

CPC分类号： C07D231/12 ,  C07D209/34 ,  C07D209/40 ,  C07D233/56 ,  C07D249/08 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D413/04 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D513/04

摘要： Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydrogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.

公开(公告)号：US06387919B1

公开(公告)日：2002-05-14

申请号：US09486960

申请日：2000-06-06

申请人： Stephen Thomas Davis ,  Scott Howard Dickerson ,  Philip Anthony Harris ,  Robert Neil Hunter, III ,  Lee Frederick Kuyper ,  Michael Joseph Luzzio ,  James Marvin Veal ,  Duncan Herrick Walker

发明人： Stephen Thomas Davis ,  Scott Howard Dickerson ,  Philip Anthony Harris ,  Robert Neil Hunter, III ,  Lee Frederick Kuyper ,  Michael Joseph Luzzio ,  James Marvin Veal ,  Duncan Herrick Walker

IPC分类号： A61K314045

CPC分类号： C07D231/12 ,  C07D209/34 ,  C07D209/40 ,  C07D233/56 ,  C07D249/08 ,  C07D401/06 ,  C07D401/12 ,  C07D403/04 ,  C07D403/12 ,  C07D405/12 ,  C07D413/04 ,  C07D471/04 ,  C07D487/04 ,  C07D491/04 ,  C07D513/04

摘要： Compounds of formula (I): wherein X is N, CH, CCF3, or C(C1-12 aliphatic); R4 is sulfonic acid, C1-12 aliphatic-sulfonyl, sulfonyl-C1-12 aliphatic, C1-12 aliphatic-sulfonyl-C1-6 aliphatic, C1-6 aliphatic-amino, R7-sulfonyl, R7 sulfonyl-C1-12 aliphatic, R7-aminosulfonyl, R7-aminosulfonyl-C1-12 aliphatic, R7-sulfonylamino, R7-sulfonylamino-C1-12 aliphatic, aminosulfonylamino, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl, di-C1-12 aliphatic amino, di-C1-12 aliphatic aminocarbonyl, di-C1-12 aliphatic aminosulfonyl-C1-12 aliphatic, (R8)1-3-Arylamino, (R8)1-3-Arylsulfonyl, (R8)1-3-Aryl-aminosulfonyl, (R8)1-3-Aryl-sulfonylamino, Het-amino, Het-sulfonyl, Het-aminosulfonyl, aminoiminoamino, or aminoiminoaminosulfonyl, R5 is hydrogen; and further wherein R4 and R5 are optionally joined to form a fused ring, pharmaceutical formulations comprising them and their use in therapy, especially in the treatment of diseases mediated by CDK2 activity, such as alopecia induced by cancer chemotherapy or radiotherapy.

摘要翻译： 式（I）化合物：其中X为N，CH，CCF 3或C（C 1-12脂族基）; R 4是磺酸，C 1-12脂族磺酰基，磺酰基-C 1-12脂族基，C 1-12脂族磺酰基-C 1-6脂族基，C 1-6脂族氨基，R 7磺酰基，R 7磺酰基-C 1-12脂族基， R7-氨基磺酰基，R7-氨基磺酰基-C1-12脂族，R7-磺酰氨基，R7-磺酰氨基-C12-12脂族，氨基磺酰基氨基，二-C1-12脂族氨基，二-C1-12脂族氨基羰基，二-C1-12脂族 氨基磺酰基，二-C 1-12脂族氨基，二-C1-12脂族氨基羰基，二C1-12脂族氨基磺酰基-C1-12脂族基，（R8）1-3 - 芳基氨基，（R8）1-3 - 芳基磺酰基，（ R8）1-3-芳基 - 氨基磺酰基，（R8）1-3-芳基 - 磺酰基氨基，Het-氨基，Het-磺酰基，Het-氨基磺酰基，氨基亚氨基氨基或氨基亚氨基磺酰基，R5是氢; 并且其中R 4和R 5任选地连接以形成稠环，包含它们的药物制剂及其在治疗中的用途，特别是用于治疗由CDK2活性介导的疾病，例如由癌症化学疗法或放射治疗引起的脱发。

公开(公告)号：US07790714B2

公开(公告)日：2010-09-07

申请号：US12759010

申请日：2010-04-13

申请人： Adnan M.M. Mjalli ,  Dharma Rao Polisetti ,  Thomas Scott Yokum ,  Kalpathy Santhosh ,  Mustafa Guzel ,  Christopher Behme ,  Stephen Thomas Davis

发明人： Adnan M.M. Mjalli ,  Dharma Rao Polisetti ,  Thomas Scott Yokum ,  Kalpathy Santhosh ,  Mustafa Guzel ,  Christopher Behme ,  Stephen Thomas Davis

IPC分类号： C07D498/02 ,  A61K31/5365

CPC分类号： C07D498/04 ,  C07D498/14

摘要： The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.

摘要翻译： 本发明提供使用式（I）的恶二唑衍生物及其药学上可接受的盐的方法，其中A，B，C，R，R 1，R 2，R 3，R 4和R 5如本文所述，并且其中所述方法 包括用于治疗和/或预防疾病和疾病如糖尿病的用途。

公开(公告)号：US20100197677A1

公开(公告)日：2010-08-05

申请号：US12759010

申请日：2010-04-13

申请人： Adnan M.M. Mjalli ,  Dharma Rao Polisetti ,  Thomas Scott Yokum ,  Kalpathy Santhosh ,  Mustafa Guzel ,  Christopher Behme ,  Stephen Thomas Davis

发明人： Adnan M.M. Mjalli ,  Dharma Rao Polisetti ,  Thomas Scott Yokum ,  Kalpathy Santhosh ,  Mustafa Guzel ,  Christopher Behme ,  Stephen Thomas Davis

IPC分类号： A61K31/5383 ,  A61P3/10

CPC分类号： C07D498/04 ,  C07D498/14

摘要： The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.

公开(公告)号：US07727983B2

公开(公告)日：2010-06-01

申请号：US12399504

申请日：2009-03-06

申请人： Adnan M. M. Mjalli ,  Dharma Rao Polisetti ,  Thomas Scott Yokum ,  Kalpathy Santhosh ,  Mustafa Guzel ,  Christopher Behme ,  Stephen Thomas Davis

发明人： Adnan M. M. Mjalli ,  Dharma Rao Polisetti ,  Thomas Scott Yokum ,  Kalpathy Santhosh ,  Mustafa Guzel ,  Christopher Behme ,  Stephen Thomas Davis

IPC分类号： C07D498/02 ,  A61K31/5365

CPC分类号： C07D498/04 ,  C07D498/14

摘要： The present invention provides oxadiazoanthracene derivatives of the formula (I), wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazoanthracene derivatives of Formula (I).

摘要翻译： 本发明提供式（I）的恶二唑并蒽衍生物，其中A，B，C，R，R 1，R 2，R 3，R 4和R 5如本文所述，包含恶二唑并蒽衍生物的药物组合物，使用恶二唑衍生物用于制备 的药物组合物，其用于治疗和/或预防疾病和疾病的方法，例如糖尿病，以及可用于制备式（I）的恶二唑衍生物的中间体。

公开(公告)号：US20100324033A1

公开(公告)日：2010-12-23

申请号：US12872580

申请日：2010-08-31

申请人： Adnan M.M. Mjalli ,  Dharma Rao Polisetti ,  Thomas Scott Yokum ,  Kalpathy Santhosh ,  Mustafa Guzel ,  Christopher Behme ,  Stephen Thomas Davis

发明人： Adnan M.M. Mjalli ,  Dharma Rao Polisetti ,  Thomas Scott Yokum ,  Kalpathy Santhosh ,  Mustafa Guzel ,  Christopher Behme ,  Stephen Thomas Davis

IPC分类号： A61K31/5383 ,  A61P3/10 ,  A61P1/12 ,  A61P3/04

CPC分类号： C07D498/04 ,  C07D498/14

摘要： The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.

摘要翻译： 本发明提供使用式（I）的恶二唑衍生物及其药学上可接受的盐的方法，其中A，B，C，R，R 1，R 2，R 3，R 4和R 5如本文所述，并且其中所述方法 包括用于治疗和/或预防疾病和疾病如糖尿病的用途。

公开(公告)号：US07906507B2

公开(公告)日：2011-03-15

申请号：US12849225

申请日：2010-08-03

申请人： Adnan M. M. Mjalli ,  Dharma Rao Polisetti ,  Thomas Scott Yokum ,  Kalpathy Santhosh ,  Mustafa Guzel ,  Christopher Behme ,  Stephen Thomas Davis

发明人： Adnan M. M. Mjalli ,  Dharma Rao Polisetti ,  Thomas Scott Yokum ,  Kalpathy Santhosh ,  Mustafa Guzel ,  Christopher Behme ,  Stephen Thomas Davis

IPC分类号： C07D498/02 ,  A61K31/5365

CPC分类号： C07D498/04 ,  C07D498/14

摘要： The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, and wherein said methods of use include uses for the treatment and/or prevention of disorders and diseases, such as diabetes.

摘要翻译： 本发明提供使用式（I）的恶二唑衍生物及其药学上可接受的盐的方法，其中A，B，C，R，R 1，R 2，R 3，R 4和R 5如本文所述，并且其中所述方法 包括用于治疗和/或预防疾病和疾病如糖尿病的用途。

公开(公告)号：US20090306063A1

公开(公告)日：2009-12-10

申请号：US12399504

申请日：2009-03-06

申请人： Adnan M.M. Mjalli ,  Dharma Rao Polisetti ,  Thomas Scott Yokum ,  Kalpathy Santhosh ,  Mustafa Guzel ,  Christopher Behme ,  Stephen Thomas Davis

发明人： Adnan M.M. Mjalli ,  Dharma Rao Polisetti ,  Thomas Scott Yokum ,  Kalpathy Santhosh ,  Mustafa Guzel ,  Christopher Behme ,  Stephen Thomas Davis

IPC分类号： A61K31/5365 ,  C07D265/34 ,  A61P3/10

CPC分类号： C07D498/04 ,  C07D498/14

摘要： The present invention provides oxadiazoanthracene derivatives of the formula (I), wherein A, B, C, R, R1, R2, R3, R4 and R5 are as herein described, pharmaceutical compositions comprising oxadiazoanthracene derivatives, use of the oxadiazoanthracene derivatives for the preparation of pharmaceutical compositions, methods of use thereof for the treatment and/or prevention of disorders and diseases, such as diabetes, and intermediates useful for the preparation of oxadiazoanthracene derivatives of Formula (I).

摘要翻译： 本发明提供式（I）的恶二唑并蒽衍生物，其中A，B，C，R，R 1，R 2，R 3，R 4和R 5如本文所述，包含恶二唑并蒽衍生物的药物组合物，使用恶二唑衍生物用于制备 的药物组合物，其用于治疗和/或预防疾病和疾病的方法，例如糖尿病，以及可用于制备式（I）的恶二唑衍生物的中间体。